Sierra Oncology Revenue and Competitors

Location

$494.1M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Sierra Oncology's estimated annual revenue is currently $9.8M per year.(i)
  • Sierra Oncology received $15.0M in venture funding in August 2018.
  • Sierra Oncology's estimated revenue per employee is $287,206
  • Sierra Oncology's total funding is $494.1M.

Employee Data

  • Sierra Oncology has 34 Employees.(i)
  • Sierra Oncology grew their employee count by -68% last year.

Sierra Oncology's People

NameTitleEmail/Phone
1
Director BiostatisticsReveal Email/Phone
2
Director Clinical Project ManagementReveal Email/Phone
3
Director Quality Assurance, Systems and ComplianceReveal Email/Phone
4
Associate Director PharmacovigilanceReveal Email/Phone
5
Senior Director, Program ManagementReveal Email/Phone
6
Senior Manager, Clinical SuppliesReveal Email/Phone
7
Clinical Site ManagerReveal Email/Phone
8
Senior Clinical Project ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$3.1M4018%$40MN/A
#2
$0.2M20%N/AN/A
#3
$1.3M17-15%N/AN/A
#4
$2.6M176%N/AN/A
#5
$12.9M835%N/AN/A
#6
$1.9M244%$89.5MN/A
#7
$2.8M186%N/AN/A
#8
$40.3M26021%N/AN/A
#9
$0.9M60%N/AN/A
#10
$0.6M4-20%N/AN/A
Add Company

What Is Sierra Oncology?

Sierra Oncology is a clinical stage drug development company advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer. Our lead product candidate, SRA737, is a potent, highly selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1). We are pursuing an innovative development plan for SRA737, which is currently being evaluated in two Phase 1/2 clinical trials in patients with advanced cancer. SRA737-01 is intended to evaluate SRA737's potential to induce synthetic lethality as monotherapy, while the SRA737-02 is intended to evaluate the combination of SRA737 potentiated by subtherapeutic, low dose gemcitabine. Concurrently, we are conducting preclinical research evaluating SRA737 in combination with other DDR-targeted agents, including PARP inhibitors, as well as with immuno-oncology therapeutics, that may guide a potential next wave of clinical development for our asset, possibly further broadening its therapeutic utility. We are also advancing SRA141, a potent, selective, orally bioavailable small molecule inhibitor of cell division cycle 7 kinase (Cdc7). SRA141 is currently undergoing preclinical research in preparation for an Investigational New Drug Application (IND) submission to the U.S. Food and Drug Administration (FDA).

keywords:N/A

$494.1M

Total Funding

34

Number of Employees

$9.8M

Revenue (est)

-68%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Sierra Oncology News

2022-04-06 - GSK acquires Sierra Oncology, betting $2B on a bone cancer drug ...

GlaxoSmithKline has agreed to acquire Sierra Oncology for $1.9 billion in a bet that an experimental drug the small biotech developed is on...

2022-04-06 - GSK Glaxo to Buy Biotech Company Sierra Oncology for $1.9 Billion ...

GlaxoSmithKline Plc agreed to buy biotech company Sierra Oncology for $1.9 billion as the U.K. drugmaker moves to strengthen its lineup of...

2022-04-06 - GSK reaches agreement to acquire late-stage biopharmaceutical ...

Sierra Oncology is a late-stage biopharmaceutical company based in San Mateo, California, on a mission to deliver targeted therapies that treat...

2021-08-09 - Sierra Oncology : Provides Update to Momelotinib Development Timeline and Closes on $34 Million in Additional Funding

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today updated guidance on the development timeline for its lead product candidate, momelotinib. The company now expects topline data from the P ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6.6M340%N/A
#2
$7.5M346%N/A
#3
$6.7M34-3%N/A
#4
$3.9M34-3%N/A
#5
$3.9M34N/AN/A

Sierra Oncology Funding

DateAmountRoundLead InvestorsReference
2005-10-20$4.2MUndisclosedApjohn Ventures, Grand AnglesArticle
2006-10-25$6.6MUndisclosedMultipleArticle
2014-01-02$11.2MUndisclosedArticle
2014-01-14$12.0MCArticle
2014-04-22$59.5MDMultipleArticle
2017-02-09$UndisclosedUndisclosedJefferies LLCArticle
2018-03-05$49.2MUndisclosedJefferiesArticle
2018-08-23$15.0MUndisclosedSilicon Valley BankArticle